ZXZhiyi Xie

Zhiyi Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhiyi Xie has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Budbazar Enkhjargal

    Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China

    1 shared publication
  • Jiping Tang

    Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China

    1 shared publication
  • John H. Zhang

    Department of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, USA

    1 shared publication
  • Lingyun Wu

    Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China

    1 shared publication
  • Matei Nathanael

    Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China

    1 shared publication
  • Qiquan Zhu

    Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Exendin-4 Preserves Blood-Brain Barrier Integrity via Glucagon-Like Peptide 1 Receptor/Activated Protein Kinase-Dependent Nuclear Factor-Kappa B/Matrix Metalloproteinase-9 Inhibition After Subarachnoid Hemorrhage in Rat

    by Zhiyi Xie, Budbazar Enkhjargal, Matei Nathanael, Lingyun Wu, Qiquan Zhu, Tongyu Zhang, Jiping Tang, John H. Zhang

    In this study, we investigated the role of Exendin-4 (Ex-4), a glucagon-like peptide 1 receptor (GLP-1R) agonist, in blood-brain barrier (BBB) disruption after subarachnoid hemorrhage (SAH) in rats. The endovascular perforation model of SAH was performed in Sprague-Dawley rats. Ex-4 was intraperitoneally injected 1 h after SAH induction. To elucidate the underlying molecular mechanism, small interfering ribonucleic acid (siRNA) for GLP-1R and Dorsomorphin, a specific inhibitor of adenosine monophosphate-activated protein kinase (AMPK), were intracerebroventricularly injected 48 h before induction of SAH correspondingly. Immunofluorescence results supported GLP-1R expressed on the endothelial cells of microvessels in the brain after SAH. Administration of Ex-4 significantly reduced brain water content and Evans blue extravasation in both hemispheres, which improved neurological scores at 24 h after SAH. In the mechanism study, Ex-4 treatment significantly increased the expression of GLP-1R, p-AMPK, IκB-α, Occludin, and Claudin-5, while the expression of p-nuclear factor-kappa B (NF-κB) p65, matrix metalloproteinase-9 (MMP-9), and albumin was significantly decreased. The effects of Ex-4 were reversed by the intervention of GLP-1R siRNA or Dorsomorphin, respectively. In conclusion, Ex-4 could preserve the BBB integrity through GLP-1R/AMPK-dependent NF-κB/MMP-9 inhibition after SAH, which should be further investigated as a potential therapeutic target in SAH.